OncoCyte Corporation with ticker code (OCX) now have 4 analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The range between the high target price and low target price is between 1.4 and 0.4 and has a mean target at 0.83. With the stocks previous close at 0.45 this now indicates there is a potential upside of 84.4%. The 50 day MA is 0.43 and the 200 moving average now moves to 0.83. The market capitalisation for the company is $54m. Visit the company website at: https://oncocyte.com
The potential market cap would be $100m based on the market concensus.
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
